Twist Bioscience Reports Record Q2 2026 Results, Raises Guidance, and Nears Profitability

South San Francisco, Calif. — May 4, 2026 — Twist Bioscience Corporation (NASDAQ: TWST), a leader in synthetic DNA production and related biotech solutions, has announced its financial results for the fiscal second quarter ended March 31, 2026. The company posted record revenues, raised its full-year guidance, and reiterated its path to profitability — all developments that are likely to be closely watched by investors and could impact the company’s share price.

Key Highlights from Q2 FY26 Results

• Record Revenue: Total Q2 revenue reached \$110.7 million, up more than 19% from \$92.8 million in Q2 FY25. This marks Twist’s 13th consecutive quarter of sequential growth.
• Segment Performance:
  • DNA Synthesis and Protein Solutions (DSPS): Revenue grew 28% year-over-year to \$53.3 million, and increased 4% sequentially over Q1 FY26.
  • NGS Applications (NGS): Revenue rose 12% year-over-year to \$57.4 million, with 9% sequential growth over Q1 FY26.
• Improved Profitability Metrics: Gross margin for Q2 FY26 improved to 51.6%, up two percentage points from the prior year’s 49.6%. The company expects to hold gross margin above 52% for the full fiscal year.
• Adjusted EBITDA: Adjusted EBITDA loss narrowed to \$(13.3) million compared to \$(14.8) million in Q2 FY25.
• Cash Position: Twist ended the quarter with approximately \$172 million in cash, cash equivalents, and short-term investments.
• Net Loss: The company reported a net loss of \$44.0 million, or \$0.71 per share, compared to a net loss of \$39.3 million, or \$0.66 per share, in Q2 FY25.
• Operating Expense Update:
  • R&D expenses decreased to \$19.7 million from \$23.9 million last year.
  • Selling, general, and administrative (SG&A) expenses rose to \$76.1 million from \$63.7 million, reflecting increased investments in commercial activities.
• Litigation Settlement: Twist reached a settlement in principle regarding a securities class action for approximately \$17.1 million. The company booked \$7.2 million in litigation settlement costs (net of recoveries) this quarter — a potentially price-sensitive development that resolves a key legal overhang.
• Customer and Product Metrics:
  • Shipped products to approximately 2,583 customers in Q2 FY26, up from 2,431 in Q2 FY25.
  • Shipped about 300,000 genes, up from 227,000 a year ago, demonstrating strong operational scaling.
• Strategic Agreements and Product Launches:
  • Entered a bispecific licensing agreement with Invenra, becoming co-exclusive provider of the B-Body® bispecific antibody platform, bolstering Twist’s antibody discovery services.
  • Named as a wet lab partner for Amazon Discovery, Amazon Web Services’ AI-powered drug discovery platform — a potentially significant commercial partnership.
  • Launched the Twist TrueAmp Library Preparation Kit and the Twist PCR-Free WGS Library Preparation Kit, broadening the company’s NGS product portfolio for clinical research.

Updated Financial Guidance for Fiscal 2026

• Full-Year Revenue: Guidance raised to \$442-447 million (17% to 19% growth), up from prior guidance of \$435-440 million.
• Gross Margin: Expected to be above 52% for the year.
• Q3 FY26 Revenue: Expected to be \$114-115 million (approximately 19% year-over-year growth at midpoint), with NGS expected to drive sequential growth and return to 20% annual growth by Q4.
• Profitability Outlook: The company reiterated its expectation to achieve adjusted EBITDA breakeven in Q4 FY26 — a critical inflection point that could be highly price-sensitive.

Important Factors for Shareholders

• Consistent, Strong Growth: Twist has delivered 13 consecutive quarters of sequential revenue growth, now at record levels. The company’s demonstrated ability to scale is a key positive for long-term shareholders.
• Margin Expansion: Gross margin improvement and the expectation to maintain >52% margin for FY26 highlight operational efficiency and pricing power.
• Path to Profitability: The company’s reiteration of adjusted EBITDA breakeven in Q4 FY26 is a major milestone. Achieving this could be a significant catalyst for the stock.
• Legal Overhang Addressed: The settlement of the securities class action suit for \$17.1 million removes an element of uncertainty that may have weighed on the share price.
• Strategic Partnerships: The collaboration with Amazon Web Services and the Invenra bispecific antibody platform agreement could open up new high-growth market opportunities for Twist, supporting long-term growth and potentially attracting new investors.
• Product Innovation: Ongoing product launches in NGS and antibody discovery keep Twist positioned at the forefront of synthetic biology and genomics research.

Financial Statements Summary

Balance Sheet Snapshot (as of March 31, 2026)

• Total Assets: \$676.2 million
• Total Liabilities: \$221.1 million
• Total Stockholders’ Equity: \$455.1 million

Looking Ahead

Twist Bioscience continues to execute on its growth strategy, with strong top-line growth, margin improvement, and a clear path to profitability. Strategic partnerships and new product launches further position the company for future expansion in key markets, including synthetic biology, genomics, diagnostics, and drug discovery. The resolution of litigation and the raised full-year guidance are likely to be seen as positive by investors. The company’s progress toward adjusted EBITDA breakeven in Q4 FY26 will be a critical factor for shareholder value and market sentiment going forward.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the company’s filings with the SEC and consult their financial advisor before making investment decisions. Forward-looking statements are subject to risks and uncertainties as described in the company’s official filings.

View Twist Bioscience Corp Historical chart here